assogenerici.org
Assogenerici - Associazione Nazionale Industrie Farmaci Generici Equivalenti
http://www.assogenerici.org/newsite
Misure anti-patent linkage: ennesimo stop. Roma, 3 agosto 2016 La Commissione Industria del Senato ha bocciato ieri pomeriggio i tre emendamenti presentati al ddl concorrenza tesi ad eliminare il meccanismo del patent linkage. L Italia resta così l ultima nazione in Europa a consentire queste pratiche volte a ritardare l ingresso dei farmaci equivalenti sul mercato, con i conseguenti mancati risparmi in termini di denaro pubblico . Così Enrique Häusermann, Presidente di Assogenerici. Roma, 15 luglio 2016...
medicinesforeurope.com
Our 5 pillars | Medicines for Europe
http://www.medicinesforeurope.com/biosimilar-medicines/our-5-pillars
REGULATORY AND LEGAL FRAMEWORK. Value added medicines Group. Biosimilar medicines were invented in Europe 20 years ago to address the pressing need for better access to biopharmaceuticals in Europe. For example, a recent study demonstrated the inequity in access to biologic medicines for treatment of rheumatoid arthritis. Because lower income countries in Europe cannot afford such therapies. Putrik et al. Ann Rheum Dis 2014;73:198-206. Rheumatoid Arthritis (RA) Market Forecast 2012. Our experience to dat...
medicinesforeurope.com
Our 5 pillars | Medicines for Europe
http://www.medicinesforeurope.com/generic-medicines/our-5-pillars
REGULATORY AND LEGAL FRAMEWORK. Value added medicines Group. See our IMS infographic on the Role of Generic Medicines in Sustaining Healthcare Systems. Generic Medicines are for Patients. Generic medicines create better value for health at many different levels:. Increasing access to medicines for all patients across therapeutic areas;. Reducing health inequalities by enabling access to patients in previously underserved markets in Europe;. Generic Medicines Stand for Quality. Generic medicines create ec...
medicinesforeurope.com
Who we are | Medicines for Europe
http://www.medicinesforeurope.com/value-added-medicines/who-we-are
REGULATORY AND LEGAL FRAMEWORK. Value added medicines Group. About the Value Added Medicines Group. The Value Added Medicines Group. A sector group of. Aims to rethink, reinvent and optimise medicines based on known molecules by bringing untapped innovation to improve care delivery. The Value Added Medicines Group adopts a complementary perspective compared to the other. Establish, in collaboration with patients, healthcare professionals and payers, a sustainable market model that incentivises R&D and ac...
assogenerici.org
Farmaco generico equivalente: cos'e'; F.A.Q.; L'angolo dell'Esperto
http://www.assogenerici.org/2011/farmaco.asp?s=1&p=1&modulo=farmaco
Cos'e' il Farmaco Generico Equivalente. PER SAPERNE DI PIU'. Medicinali equivalenti e medicinali di marca. Vademecum della qualita' dei farmaci generici. Il Farmaco Generico Equivalente: Cos'è. Esattamente come la specialità medicinale da cui derivano, i medicinali generici possono essere sia da banco e dunque acquistabili liberamente, che prescrivibili; in questo caso sarà necessaria, come per la specialità medicinale corrispondente, la ricetta medica. Statuto e Codice Deontologico. ASSOGENERICI - Assoc...
bogin.org
Nieuws - Biosimilars en generieke geneesmiddelenindustrie Nederland (BOGIN)
http://www.bogin.org/nieuws
Biosimilars en generieke geneesmiddelenindustrie Nederland. Jan Pieterszoon Coenstraat 7. 2595 WP Den Haag. T 31 (0)70 - 799 92 37. De opgevraagde pagina kon niet worden gevonden.
bogin.info
Begrippen - Biosimilars en generieke geneesmiddelenindustrie Nederland (BOGIN)
http://www.bogin.info/begrippen
Biosimilars en generieke geneesmiddelenindustrie Nederland. Jan Pieterszoon Coenstraat 7. 2595 WP Den Haag. T 31 (0)70 - 799 92 37. Hier treft u een handige lijst met begrippen en afkortingen uit de wereld van generieke geneesmiddelen*. In chemistry, a moiety is a group of atoms forming part of a molecule. In the case of a pharmaceutical product, the active moiety is that part of the molecule of an active substance which gives it its therapeutic effect. An off-patent biological medicinal product which is...
bogin.info
Leden - Biosimilars en generieke geneesmiddelenindustrie Nederland (BOGIN)
http://www.bogin.info/leden
Biosimilars en generieke geneesmiddelenindustrie Nederland. Jan Pieterszoon Coenstraat 7. 2595 WP Den Haag. T 31 (0)70 - 799 92 37. Bogin telt acht leden waarmee wij zo'n 90% van de generieke geneesmiddelenindustrie in Nederland vertegenwoordigen:.
bogin.nl
Ontwikkeling generiek - Biosimilars en generieke geneesmiddelenindustrie Nederland (BOGIN)
http://www.bogin.nl/ontwikkeling-generiek
Biosimilars en generieke geneesmiddelenindustrie Nederland. Jan Pieterszoon Coenstraat 7. 2595 WP Den Haag. T 31 (0)70 - 799 92 37. Hoe wordt het generiek geneesmiddel ontwikkeld? Gemiddeld wordt door generieke geneesmiddelenfabrikanten 7,4% van de omzet besteed aan Research. Development (Bron: Global Generics Guide, Datamonitor). Hieronder worden de diverse fasen beschreven die leiden tot de productie van het generieke geneesmiddel. Fase 1: Ontwikkeling actieve stof. Allereerst moet vastgesteld worden o...
bogin.nl
Nieuwsbrief - Biosimilars en generieke geneesmiddelenindustrie Nederland (BOGIN)
http://www.bogin.nl/nieuwsbrief
Biosimilars en generieke geneesmiddelenindustrie Nederland. Jan Pieterszoon Coenstraat 7. 2595 WP Den Haag. T 31 (0)70 - 799 92 37. Klik hier om u aan te melden. Bogin Bericht - juli 2016. Bogin Bericht - maart 2016. Bogin Bericht - februari 2016. Bogin Bericht - november 2015. Bogin Bericht - oktober 2015#2. Bogin Bericht - oktober 2015. Bogin Bericht - september 2015. Bogin Bericht - juli 2015. Bogin Bericht - juni 2015. Bogin Bericht - mei 2015. Bogin Bericht - april 2015. Bogin Bericht - februari 2015.
SOCIAL ENGAGEMENT